BCI
AXSM icon

Brinker Capital Investments’s Axsome Therapeutics AXSM Stock Holding History

Brinker Capital Investments’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$260K Sell
1,536
-147
-9% -$25.4K ﹤0.01% 1723
2025
Q4 		$307K Sell
1,683
-506
-23% -$70.6K ﹤0.01% 1802
2025
Q3 		$266K Buy
2,189
+53
+2% +$5.97K ﹤0.01% 1829
2025
Q2 		$223K Sell
2,136
-130
-6% -$13.8K ﹤0.01% 1839
2025
Q1 		$264K Buy
+2,266
New +$258K ﹤0.01% 1683
2024
Q4 		– Sell
-2,751
Closed -$247K – 1826
2024
Q3 		$247K Sell
2,751
-53
-2% -$4.63K ﹤0.01% 1615
2024
Q2 		$226K Sell
2,804
-179
-6% -$13.3K ﹤0.01% 1581
2024
Q1 		$238K Buy
2,983
+60
+2% +$5.04K ﹤0.01% 1550
2023
Q4 		$260K Sell
2,923
-440
-13% -$29.4K ﹤0.01% 1467
2023
Q3 		$235K Buy
3,363
+19
+0.6% +$1.42K ﹤0.01% 1488
2023
Q2 		$240K Buy
+3,344
New +$247K ﹤0.01% 1493
2023
Q1 		– Sell
-2,681
Closed -$207K – 1559
2022
Q4 		$207K Sell
2,681
-3,305
-55% -$198K ﹤0.01% 1284
2022
Q3 		$267K Buy
+5,986
New +$299K 0.01% 1165
2021
Q1 		– Sell
-4,507
Closed -$367K – 1170
2020
Q4 		$367K Buy
+4,507
New +$337K 0.01% 900

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brinker Capital Investments's AXSM Position: Q1 2026 in Review

Brinker Capital Investments reduced its Axsome Therapeutics (AXSM) stake by 8.7% in Q1 2026, selling an estimated $25.4K and leaving 1,536 shares worth $260K. The position accounts for ﹤0.01% of the portfolio, ranked #1723.

Brinker Capital Investments first reported a position in AXSM in Q4 2020 and has held it in 14 quarters since. The position peaked at $367K in Q4 2020. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Brinker Capital Investments held 1,536 shares of Axsome Therapeutics worth $260K as of Q1 2026.
  • Brinker Capital Investments sold 147 Axsome Therapeutics shares in Q1 2026, an estimated $25.4K.
  • Axsome Therapeutics made up ﹤0.01% of Brinker Capital Investments's portfolio in Q1 2026, its #1723 holding.
  • Brinker Capital Investments first reported a position in Axsome Therapeutics in Q4 2020 and has held it in 14 quarters since.
  • Brinker Capital Investments's Axsome Therapeutics position peaked at $367K in Q4 2020.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Brinker Capital Investments's 13F filing for Q1 2026, filed 13 May 2026.